US WorldMeds 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases  2 Products   10 Trials   231 News 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lucemyra (lofexidine) / US WorldMeds, Stada
2007-002352-41: Lyhyt ja pitkä buprenorfiini-naloksoni -hoito suonensisäisen buprenorfiiniriippuvuuden vieroitushoidossa. Satunnaistettu kontrolloitu tutkimus

Ongoing
4
120
Europe
Suboxone, BritLofex
Helsingin Diakonissalaitos
Opiaattiriippuvuus, buprenorfiinin suonensisäinen väärinkäyttö
 
 
Bridge, NCT04325659: An Innovative Intervention for OUD Treatment

Recruiting
2/3
75
US
Bridge Device, NSS-2 Bridge Device, Lofexidine, Lucemyra, Placebo, Sham Bridge Device, Sham NSS-2 Bridge Device
Johns Hopkins University, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Opioid-Related Disorders, Opioid Dependence, Opioid Addiction, Opioid Withdrawal
10/25
10/25
PGB-LOF, NCT04218240: Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal

Completed
2
90
US
Pregabalin 200 MG capsules, lyrica, Placebo oral tablet, Lofexidine 0.18Mg Tab, lucemyra
University of Pennsylvania
Opioid Withdrawal
03/23
03/23
NCT03718065: Impact of Lofexidine on Stress, Craving and Opioid Use

Completed
2
112
US
Lofexidine, Lucemyra, Placebo
Medical University of South Carolina, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Opioid-use Disorder, Opiate Dependence
01/24
01/24
NCT06047834: Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids

Active, not recruiting
2
24
US
Standard of Care with Lofexidine, Standard of Care without Lofexidine
USWM, LLC (dba US WorldMeds), National Institute on Drug Abuse (NIDA)
Opioid Withdrawal (Disorder)
05/25
10/26
NCT04360681: Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans

Recruiting
2
120
US
Lofexidine, LFX, Placebo oral tablet, PLB
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, United States Department of Defense, RTI International, Michael E. DeBakey VA Medical Center, USWM, LLC (dba US WorldMeds), Foundation for Advancing Veterans' Health Research
Post Traumatic Stress Disorder, Opioid-use Disorder
12/25
12/25
NCT05027919: Assessing a Clinically-meaningful Opioid Withdrawal Phenotype

Recruiting
2
60
US
Morphine, Naloxone + lofexidine pretreatment, Naloxone + placebo pretreatment, Lofexidine
University of Maryland, Baltimore, National Institute on Drug Abuse (NIDA)
Opioid Withdrawal, Opioid Use Disorder, Opioid Craving
11/25
02/26
UH3, NCT05995535: Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

Recruiting
2
150
US
LFX/PGB, Lucemyra, lyrica, LFX/PLA-PGB, placebo pregabalin
University of Pennsylvania
Opiate Withdrawal Syndrome, Opioid Use
08/26
08/26
NCT05511909: Evaluating Buspirone to Treat Opioid Withdrawal

Recruiting
2
100
US
Buspirone, Lofexidine, Placebo
Johns Hopkins University
Opioid Use Disorder, Opioid Withdrawal, Opioid Craving, Anxiety
01/27
03/27
NCT05712707: Sublingual Dexmedetomidine for Treating Opioid Withdrawal

Recruiting
1/2
160
US
BXCL501 (180 micrograms), BXCL501 (240 micrograms), Placebo, Lofexidine (Positive Control)
New York State Psychiatric Institute, BioXcel Therapeutics Inc, Yale University, Clinilabs, Inc., National Institute on Drug Abuse (NIDA), CenExel HRI
Opioid Use Disorder, Opioid Withdrawal
06/25
07/25
USWM-LX1-1014, NCT06711640: A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects

Not yet recruiting
1
16
US
LUCEMYRA (lofexidine) tablets
USWM, LLC (dba US WorldMeds), National Institute on Drug Abuse (NIDA)
Opioid Withdrawal (Disorder), Opioid Use Disorder
01/26
02/26
RESTORE, NCT05053503: Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder

Completed
N/A
108
US
Sparrow Ascent Therapy System, Lofexidine, Extended-release injectable naltrexone
Spark Biomedical, Inc., Hazelden Betty Ford Foundation, Gaudenzia, Inc.
Opioid-use Disorder, Opioid Withdrawal
04/25
04/25
Zimhi (naloxone injection) / DMK Pharma, US WorldMeds
No trials found
Symjepi (epinephrine) / DMK Pharma, US WorldMeds
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lucemyra (lofexidine) / US WorldMeds, Stada
2007-002352-41: Lyhyt ja pitkä buprenorfiini-naloksoni -hoito suonensisäisen buprenorfiiniriippuvuuden vieroitushoidossa. Satunnaistettu kontrolloitu tutkimus

Ongoing
4
120
Europe
Suboxone, BritLofex
Helsingin Diakonissalaitos
Opiaattiriippuvuus, buprenorfiinin suonensisäinen väärinkäyttö
 
 
Bridge, NCT04325659: An Innovative Intervention for OUD Treatment

Recruiting
2/3
75
US
Bridge Device, NSS-2 Bridge Device, Lofexidine, Lucemyra, Placebo, Sham Bridge Device, Sham NSS-2 Bridge Device
Johns Hopkins University, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Opioid-Related Disorders, Opioid Dependence, Opioid Addiction, Opioid Withdrawal
10/25
10/25
PGB-LOF, NCT04218240: Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal

Completed
2
90
US
Pregabalin 200 MG capsules, lyrica, Placebo oral tablet, Lofexidine 0.18Mg Tab, lucemyra
University of Pennsylvania
Opioid Withdrawal
03/23
03/23
NCT03718065: Impact of Lofexidine on Stress, Craving and Opioid Use

Completed
2
112
US
Lofexidine, Lucemyra, Placebo
Medical University of South Carolina, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Opioid-use Disorder, Opiate Dependence
01/24
01/24
NCT06047834: Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids

Active, not recruiting
2
24
US
Standard of Care with Lofexidine, Standard of Care without Lofexidine
USWM, LLC (dba US WorldMeds), National Institute on Drug Abuse (NIDA)
Opioid Withdrawal (Disorder)
05/25
10/26
NCT04360681: Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans

Recruiting
2
120
US
Lofexidine, LFX, Placebo oral tablet, PLB
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, United States Department of Defense, RTI International, Michael E. DeBakey VA Medical Center, USWM, LLC (dba US WorldMeds), Foundation for Advancing Veterans' Health Research
Post Traumatic Stress Disorder, Opioid-use Disorder
12/25
12/25
NCT05027919: Assessing a Clinically-meaningful Opioid Withdrawal Phenotype

Recruiting
2
60
US
Morphine, Naloxone + lofexidine pretreatment, Naloxone + placebo pretreatment, Lofexidine
University of Maryland, Baltimore, National Institute on Drug Abuse (NIDA)
Opioid Withdrawal, Opioid Use Disorder, Opioid Craving
11/25
02/26
UH3, NCT05995535: Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

Recruiting
2
150
US
LFX/PGB, Lucemyra, lyrica, LFX/PLA-PGB, placebo pregabalin
University of Pennsylvania
Opiate Withdrawal Syndrome, Opioid Use
08/26
08/26
NCT05511909: Evaluating Buspirone to Treat Opioid Withdrawal

Recruiting
2
100
US
Buspirone, Lofexidine, Placebo
Johns Hopkins University
Opioid Use Disorder, Opioid Withdrawal, Opioid Craving, Anxiety
01/27
03/27
NCT05712707: Sublingual Dexmedetomidine for Treating Opioid Withdrawal

Recruiting
1/2
160
US
BXCL501 (180 micrograms), BXCL501 (240 micrograms), Placebo, Lofexidine (Positive Control)
New York State Psychiatric Institute, BioXcel Therapeutics Inc, Yale University, Clinilabs, Inc., National Institute on Drug Abuse (NIDA), CenExel HRI
Opioid Use Disorder, Opioid Withdrawal
06/25
07/25
USWM-LX1-1014, NCT06711640: A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects

Not yet recruiting
1
16
US
LUCEMYRA (lofexidine) tablets
USWM, LLC (dba US WorldMeds), National Institute on Drug Abuse (NIDA)
Opioid Withdrawal (Disorder), Opioid Use Disorder
01/26
02/26
RESTORE, NCT05053503: Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder

Completed
N/A
108
US
Sparrow Ascent Therapy System, Lofexidine, Extended-release injectable naltrexone
Spark Biomedical, Inc., Hazelden Betty Ford Foundation, Gaudenzia, Inc.
Opioid-use Disorder, Opioid Withdrawal
04/25
04/25
Zimhi (naloxone injection) / DMK Pharma, US WorldMeds
No trials found
Symjepi (epinephrine) / DMK Pharma, US WorldMeds
No trials found

Download Options